Blood pressure drug tested to prevent transplant complication
NCT ID NCT02338232
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked severe GVHD cases and side effects like low blood pressure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- telmisartan (Micardis)
- What this could lead to
- If it worked, telmisartan could offer a new way to prevent GVHD after stem cell transplants, reducing severe complications.
- What could go wrong
- The trial was terminated early with only 32 participants, so results are limited. Telmisartan may not be effective or could cause side effects like low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- A shot at safer CAR t: early brain protection for lymphoma patients?